UAE GLP-1 buyer's guide 2026: every Dubai and Abu Dhabi route, scored honestly

The UAE GLP-1 market is supply-led right now. April 2026 saw Foundayo (oral GLP-1) approved for UAE distribution, the first market outside the United States to get it. Wegovy holds about 83 percent of regional share according to Saudi distribution data; Mounjaro is the fastest-growing line. Insurance generally does not cover weight-loss indications, so almost all of this is cash-pay. That changes the calculus: there is no insurance arbitrage to play. The price you see is the price you pay, and the variance comes from what is bundled around the medication.

This guide covers the eight UAE providers that scored well in our rubric audit, what is actually being sold, and how to pick.

What is actually being sold

UAE private GLP-1 sits in three brackets:

Bracket 1: Nurse-dispatch telehealth. You sign up online, a nurse comes to your home for the consultation and the first injection, the prescription is handled remotely by a DHA or DOH-licensed prescriber. AED 549 to AED 1,490 per month at typical doses. Zero clinic visits.

Bracket 2: Clinic plus bloodwork. You visit a DHA / DOH-licensed clinic, get an endocrinology-led consultation, baseline labs, then the prescription. AED 1,690 to AED 3,800 per month. Right answer if you want medical oversight beyond a paper prescription.

Bracket 3: Longevity stack. Premium biohacker clinic. CGM, body composition, peptide stack alongside GLP-1, dietitian, sometimes a behavioural psychologist. AED 3,800 to AED 9,000 per month. Right answer if the GLP-1 is one piece of a larger programme.

Most users want bracket 1 or 2. Bracket 3 is for the longevity-cohort customer who treats GLP-1 as one tool in a stack.

What our 11-signal rubric scored them on

Our rubric is public. Below is how we scored the UAE leaders.

Metabolic.Health — 74/100. Highest UAE score in our audit. First in the UAE outside the US to dispense Foundayo (April 2026 approval). Rebranded February 2026 from GluCare diabetes-only to a hybrid metabolic platform with their "Metabolic OS" wraparound. Endocrinology-led, DHA-licensed. Routable as the lead UAE match for users wanting the supply edge.

Endocare — 70/100. Endocrinology lead Dr. Hecham Harb, with Prof. Filip Knop of Copenhagen on the advisory side. Published 3 to 4 kg per month outcomes. Transparent Wegovy / Ozempic / Mounjaro pricing. Routable for users wanting clinical depth.

Zone.Health — 72/100. Continuous-metabolic-monitoring + GLP-1 bundle, at-home blood draw + CGM included. 13 percent body weight loss in 6 months published. Sister brand to Metabolic.Health. Routable when the user wants the full data-backed programme.

DarDoc — 68/100. At-home nurse-dispatch model, AED 149 entry pricing for the first consultation. Hub71 + Flat6Labs-backed, ADQ alumnus. Routable for the no-clinic-visit cohort.

Valeo Health — 66/100. Multi-country (UAE / KSA / Kuwait / Qatar), proprietary "Longevity Score", at-home GLP-1 nurse admin alongside a peptide stack. Routable for users in adjacent markets or wanting cross-border continuity.

Limitless Human — 66/100. Dr. Elie Abirached, Harvard-trained, faculty at Geneva College of Longevity. Proprietary "Four Domains of Precision Peptide Therapy" framework. Premium tier. Routable for the longevity-stack cohort.

We also audited Hortman Clinics, Novomed, King's College Hospital Dubai, Allure Weightloss, Cleveland Clinic Abu Dhabi, and Clinique La Prairie's Dubai longevity hub. They scored 56 to 64 and sit in the long tail; we route there only on specific user signals (perimenopause protocol → Hortman, hospital trust → King's College or Cleveland, single-focus weight clinic → Allure).

Per-route monthly cost, April 2026

| Route | Provider examples | Monthly AED | What you get | |---|---|---|---| | Nurse-dispatch entry | DarDoc | 549 to 990 | First-month at 2.5 to 5mg, at-home injection, remote prescription | | Nurse-dispatch maintenance | DarDoc, Valeo Health | 990 to 1,490 | 5 to 7.5mg ongoing, repeat home visits | | Hybrid clinic | Metabolic.Health, Endocare | 1,690 to 2,800 | DHA-licensed consultation, baseline labs, ongoing dose adjustment | | Premium clinic | Endocare (top tier), Hortman | 2,800 to 3,800 | Full endocrinology workup, programme-level oversight | | Longevity stack | Zone.Health, Limitless Human | 3,800 to 9,000 | CGM + peptide stack + dietitian + GLP-1 | | Hospital outpatient | King's College Dubai, Cleveland AD | 3,500 to 7,500 | Institutional trust, slower booking, full medical record integration |

The match email from Panya names the exact effective number for the route we recommend, after applying any first-month or programme bundling.

Foundayo (oral GLP-1) — what changed

Foundayo is Eli Lilly's oral tirzepatide formulation, approved in the US in late 2025 and in the UAE in April 2026. It is the first oral GLP-1 in the UAE distribution. Mechanism is identical to injectable tirzepatide; the trade-off is a higher pill burden (daily dosing) and slightly different absorption pharmacokinetics.

Why it matters for matching: users who refuse needles previously had no GLP-1 option in the UAE. Foundayo opens that door. Right now, Metabolic.Health is the only UAE provider stocking Foundayo at the time of writing. Endocare and DarDoc have signalled stocking by Q3 2026. If oral matters to you, the routing is narrow.

Regulatory posture you should know about

UAE GLP-1 prescribing requires:

• DHA, DOH, or MOH-AE licensed prescriber. Every provider above qualifies. Verify on the DHA Sheryan portal or DOH equivalent.
• Source from authorised UAE distribution. Eli Lilly distributes Mounjaro in the UAE through MoH-AE registered channels. Same for Novo Nordisk and Wegovy. Off-channel sourcing exists but Panya does not route there.
• No insurance-funded weight-loss claims. This is a structural feature of UAE health insurance. If a provider says they can get your GLP-1 covered through insurance, that is almost always a misunderstanding (diabetes diagnosis can route to insurance for Ozempic, not for weight loss).

There is no UAE equivalent of MHRA enforcement actions on advertising for the moment. Marketing language is more aggressive on average than UK; that does not necessarily reflect underlying clinical practice.

How to pick

You want the lowest friction, no clinic visit. DarDoc or Valeo Health. AED 549 to 1,490 covers entry and maintenance, nurse comes to you.

You want endocrinology-led clinical depth. Endocare or Metabolic.Health. AED 1,690 to 2,800 covers consultation + bloodwork + ongoing supervision.

You specifically want oral GLP-1 (Foundayo). Metabolic.Health is the only currently-stocking provider as of April 2026.

You want the full longevity stack. Zone.Health or Limitless Human. AED 3,800 to 9,000 with CGM, peptide stack, dietitian, behavioural psych.

You want institutional hospital trust. King's College Dubai or Cleveland Clinic Abu Dhabi. Higher AED, slower booking, fuller medical-record integration.

You want the woman-led perimenopause framing specifically. Hortman Clinics. They prescribe semaglutide + tirzepatide + AOD-9604 explicitly as a peri / menopause protocol, an angle few others in the region cover.

What we are not covering here

Off-channel sourcing (Iran-shipped Wegovy, India-shipped Ozempic, Russia or Turkey routes). These exist but Panya does not route there. The price gap to legitimate UAE distribution is small enough that the legal and quality risk is not worth it for a typical user. If you are inside a regulated industry where pharmaceutical provenance matters, stay on the named UAE providers above.

KSA / Saudi Arabia. The Saudi GLP-1 market is comparable in size and dynamics, but the prescribing environment differs (more brand-locked, less competition). Panya does not currently route there; we will when our cohort-5 audit lands.

Sources we audited against

• DHA Sheryan licensed-prescriber portal
• MoH-AE pharmaceutical-registry filings
• Each provider's published pricing page (April 2026)
• Foundayo UAE approval announcement (Eli Lilly press, January 2026)
• HealthcareMEA reporting on UAE metabolic-clinic landscape
• Cohort-4 outreach research, internal

Updated April 2026. Refreshed quarterly.

If a number has shifted or a provider should be reclassified, email partner@panya.health and we will update with a public changelog.